BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155-66. [PMID: 25399658 DOI: 10.1056/NEJMoa1409312] [Cited by in Crossref: 1207] [Cited by in F6Publishing: 236] [Article Influence: 172.4] [Reference Citation Analysis]
Number Citing Articles
1 Yeh RW, Kereiakes DJ, Steg PG, Cutlip DE, Croce KJ, Massaro JM, Mauri L; DAPT Study Investigators. Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention.J Am Coll Cardiol. 2017;70:2213-2223. [PMID: 29073947 DOI: 10.1016/j.jacc.2017.09.011] [Cited by in Crossref: 69] [Cited by in F6Publishing: 43] [Article Influence: 17.3] [Reference Citation Analysis]
2 Serebruany V, Kim MH, Thevathasan C, Marciniak T. Assessing Cancer Signal during Oral Antiplatelet Therapy in the Food and Drug Administration Adverse Event Reporting System: Mission Impossible. TH Open 2018;2:e28-32. [PMID: 31249926 DOI: 10.1055/s-0037-1615253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Iqbal J, Serruys PW. Optimal medical therapy is vital for patients with coronary artery disease and acute coronary syndromes regardless of revascularization strategy. Ann Transl Med 2017;5:140. [PMID: 28462220 DOI: 10.21037/atm.2017.02.15] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
4 Gibler WB, Racadio JM, Hirsch AL, Roat TW. Continuum of Care for Acute Coronary Syndrome: Optimizing Treatment for ST-Elevation Myocardial Infarction and Non-St-Elevation Acute Coronary Syndrome. Crit Pathw Cardiol 2018;17:114-38. [PMID: 30044253 DOI: 10.1097/HPC.0000000000000151] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation 2019;140:240-61. [PMID: 31116032 DOI: 10.1161/CIRCULATIONAHA.119.040167] [Cited by in Crossref: 162] [Cited by in F6Publishing: 31] [Article Influence: 81.0] [Reference Citation Analysis]
6 Jeger RV, Pfisterer M, Vogt DR, Galatius S, Abildgaard U, Naber C, Alber H, Eberli F, Kurz DJ, Pedrazzini G, Vuilliomenet A, Weilenmann D, Rickli H, Hansen KW, Rickenbacher P, Conen D, Müller C, Osswald S, Gilgen N, Kaiser C. Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II. PLoS One 2019;14:e0210821. [PMID: 30645635 DOI: 10.1371/journal.pone.0210821] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Sharma AN, Deyell JS, Sharma SN, Barseghian A. Role of and Recent Evidence for Antiplatelet Therapy in Prevention of Cardiovascular Disease in Diabetes. Curr Cardiol Rep 2019;21:78. [PMID: 31254105 DOI: 10.1007/s11886-019-1168-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
8 Abtan J, Bhatt DL, Elbez Y, Sorbets E, Eagle K, Reid CM, Baumgartner I, Wu D, Hanson ME, Hannachi H, Singhal PK, Steg PG, Ducrocq G; REACH Registry Investigators. Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the REACH Registry. Clin Cardiol 2017;40:710-8. [PMID: 28520087 DOI: 10.1002/clc.22721] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
9 Jang JY, Shin DH, Kim JS, Hong SJ, Ahn CM, Kim BK, Ko YG, Choi D, Hong MK, Park KW, Gwon HC, Kim HS, Jang Y. Optimal duration of DAPT after second-generation drug-eluting stent in acute coronary syndrome. PLoS One 2018;13:e0207386. [PMID: 30475845 DOI: 10.1371/journal.pone.0207386] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
10 Krackhardt F, Waliszewski M, Rischner J, Piot C, Pansieri M, Ruiz-Poveda FL, Boxberger M, Noutsias M, Ríos XF, Kherad B. Nine-month clinical outcomes in patients with diabetes treated with polymer-free sirolimus-eluting stents and 6‑month vs. 12‑month dual-antiplatelet therapy (DAPT). Herz 2019;44:433-9. [PMID: 29356832 DOI: 10.1007/s00059-017-4675-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Gargiulo G, Windecker S, da Costa BR, Feres F, Hong MK, Gilard M, Kim HS, Colombo A, Bhatt DL, Kim BK, Morice MC, Park KW, Chieffo A, Palmerini T, Stone GW, Valgimigli M. Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. BMJ 2016;355:i5483. [PMID: 27811064 DOI: 10.1136/bmj.i5483] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 6.6] [Reference Citation Analysis]
12 Berger JS. Oral Antiplatelet Therapy for Secondary Prevention of Acute Coronary Syndrome. Am J Cardiovasc Drugs 2018;18:457-72. [PMID: 29987548 DOI: 10.1007/s40256-018-0291-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
13 Wimmer NJ, Dufour AB, Cho K, Gagnon DR, Quach L, Ly S, Do JM, Ostrowski S, Michael Gaziano J, Faxon DP, Kinlay S. Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting. Catheter Cardiovasc Interv 2017;89:1176-84. [PMID: 27860195 DOI: 10.1002/ccd.26831] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
14 Costa F, Valgimigli M. The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall short. Cardiovasc Diagn Ther 2018;8:630-46. [PMID: 30498687 DOI: 10.21037/cdt.2018.10.01] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
15 Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L; DAPT Study Investigators. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA 2016;315:1735-49. [PMID: 27022822 DOI: 10.1001/jama.2016.3775] [Cited by in Crossref: 514] [Cited by in F6Publishing: 311] [Article Influence: 102.8] [Reference Citation Analysis]
16 Gremmel T, Michelson AD, Frelinger AL III, Bhatt DL. Novel aspects of antiplatelet therapy in cardiovascular disease. Res Pract Thromb Haemost 2018;2:439-49. [PMID: 30046748 DOI: 10.1002/rth2.12115] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
17 Xie JX, Winchester DE, Phillips LM, Hachamovitch R, Berman DS, Blankstein R, Di Carli MF, Miller TD, Al-Mallah MH, Shaw LJ. The elusive role of myocardial perfusion imaging in stable ischemic heart disease: Is ISCHEMIA the answer? J Nucl Cardiol 2017;24:1610-8. [PMID: 28752313 DOI: 10.1007/s12350-017-0963-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Gajulapalli RD, Dias S, Pattanshetty DJ, Athappan G. Optimal duration of dual antiplatelet therapy after drug eluting stent implantation: a network meta-analysis. Anatol J Cardiol 2017;18:251-60. [PMID: 29076813 DOI: 10.14744/AnatolJCardiol.2017.7672] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Carrabba N, Parodi G, Marcucci R, Valenti R, Gori AM, Migliorini A, Comito V, Bellandi B, Abbate R, Gensini GF, Antoniucci D. Bleeding events and maintenance dose of prasugrel: BLESS pilot study. Open Heart 2016;3:e000460. [PMID: 27843564 DOI: 10.1136/openhrt-2016-000460] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
20 Luo L, Fu M, Li Y, Chen Z, Yu J, Luo J, Hu S, Tu L, Xu X. The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention. Clin Cardiol 2020;43:235-41. [PMID: 31777973 DOI: 10.1002/clc.23305] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Sharma PK, Chhatriwalla AK, Cohen DJ, Jang JS, Baweja P, Gosch K, Jones P, Bach RG, Arnold SV, Spertus JA. Predicting long-term bleeding after percutaneous coronary intervention. Catheter Cardiovasc Interv 2017;89:199-206. [PMID: 27037854 DOI: 10.1002/ccd.26529] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
22 Lucotti S, Muschel RJ. Platelets and Metastasis: New Implications of an Old Interplay. Front Oncol 2020;10:1350. [PMID: 33042789 DOI: 10.3389/fonc.2020.01350] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
23 Flannery L, Liu R, Elmariah S. Dual Antiplatelet Therapy: How Long Is Long Enough? Curr Treat Options Cardiovasc Med 2019;21:17. [PMID: 30929096 DOI: 10.1007/s11936-019-0721-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Serebruany V, Tanguay JF. Misreported Cancer Deaths in PLATO Trial. J Clin Med 2021;10:3140. [PMID: 34300305 DOI: 10.3390/jcm10143140] [Reference Citation Analysis]
25 Chen YT, Chen HT, Hsu CY, Chao PW, Kuo SC, Ou SM, Shih CJ. Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis. Clin J Am Soc Nephrol 2017;12:262-71. [PMID: 28174317 DOI: 10.2215/CJN.04430416] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 4.8] [Reference Citation Analysis]
26 Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, Ohya M, Suwa S, Takagi K, Nanasato M, Hata Y, Yagi M, Suematsu N, Yokomatsu T, Takamisawa I, Doi M, Noda T, Okayama H, Seino Y, Tada T, Sakamoto H, Hibi K, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Hanaoka KI, Morino Y, Kozuma K, Kadota K, Furukawa Y, Nakagawa Y, Kimura T; STOPDAPT-2 Investigators. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. JAMA 2019;321:2414-27. [PMID: 31237644 DOI: 10.1001/jama.2019.8145] [Cited by in Crossref: 279] [Cited by in F6Publishing: 180] [Article Influence: 139.5] [Reference Citation Analysis]
27 Dellborg M, Bonaca MP, Storey RF, Steg PG, Im KA, Cohen M, Bhatt DL, Oude Ophuis T, Budaj A, Hamm C, Spinar J, Kiss RG, Lopez-Sendon J, Kamensky G, Van de Werf F, Ardissino D, Kontny F, Montalescot G, Johanson P, Bengtsson O, Himmelmann A, Braunwald E, Sabatine MS. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. Eur Heart J Cardiovasc Pharmacother 2019;5:200-6. [PMID: 31218354 DOI: 10.1093/ehjcvp/pvz020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
28 Han YL. De-escalation of anti-platelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a narrative review. Chin Med J (Engl) 2019;132:197-210. [PMID: 30614864 DOI: 10.1097/CM9.0000000000000047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
29 Gillette M, Morneau K, Hoang V, Virani S, Jneid H. Antiplatelet Management for Coronary Heart Disease: Advances and Challenges. Curr Atheroscler Rep 2016;18:35. [PMID: 27139709 DOI: 10.1007/s11883-016-0581-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
30 Misumida N, Abo-Aly M, Kim SM, Ogunbayo GO, Abdel-Latif A, Ziada KM. Efficacy and safety of short-term dual antiplatelet therapy (≤6 months) after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis of randomized controlled trials. Clin Cardiol 2018;41:1455-62. [PMID: 30225978 DOI: 10.1002/clc.23075] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
31 Cho SW, Franchi F, Angiolillo DJ. Role of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations. Ther Adv Hematol 2019;10:2040620719861475. [PMID: 31321012 DOI: 10.1177/2040620719861475] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Terrier J, Daali Y, Fontana P, Csajka C, Reny JL. Towards Personalized Antithrombotic Treatments: Focus on P2Y12 Inhibitors and Direct Oral Anticoagulants. Clin Pharmacokinet 2019;58:1517-32. [PMID: 31250210 DOI: 10.1007/s40262-019-00792-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
33 Lindholm D, Hagström E, James SK, Becker RC, Cannon CP, Himmelmann A, Katus HA, Maurer G, López-Sendón JL, Steg PG, Storey RF, Siegbahn A, Wallentin L. Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. J Am Heart Assoc 2017;6:e005580. [PMID: 28411246 DOI: 10.1161/JAHA.117.005580] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
34 Fanaroff AC, Roe MT. Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease. Drug Saf 2016;39:715-27. [PMID: 27028617 DOI: 10.1007/s40264-016-0421-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
35 Ziada KM, Abdel-Latif AK, Charnigo R, Moliterno DJ. Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials. Catheter Cardiovasc Interv 2016;87:722-32. [PMID: 26309050 DOI: 10.1002/ccd.26110] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
36 Thiele H, Jobs A. [ESC guidelines 2020: acute coronary syndrome without persistent ST-segment elevation : What is new?]. Herz 2021;46:3-13. [PMID: 33236199 DOI: 10.1007/s00059-020-05002-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Vranckx P, Leebeek FW, Tijssen JG, Koolen J, Stammen F, Herman JP, de Winter RJ, van T Hof AW, Backx B, Lindeboom W, Kim SY, Kirsch B, van Eickels M, Misselwitz F, Verheugt FW. Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease. The X-PLORER trial. Thromb Haemost 2015;114:258-67. [PMID: 25925992 DOI: 10.1160/TH15-01-0061] [Cited by in Crossref: 26] [Cited by in F6Publishing: 3] [Article Influence: 4.3] [Reference Citation Analysis]
38 van der Sangen NMR, Rozemeijer R, Chan Pin Yin DRPP, Valgimigli M, Windecker S, James SK, Buccheri S, Ten Berg JM, Henriques JPS, Voskuil M, Kikkert WJ. Patient-tailored antithrombotic therapy following percutaneous coronary intervention. Eur Heart J 2021;42:1038-46. [PMID: 33515031 DOI: 10.1093/eurheartj/ehaa1097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Kawamura Y, Tamura N, Goto S, Goto S. Computer Simulation of Platelet Adhesion around Stent Struts in the Presence and Absence of Tissue Defects around Them. J Interv Cardiol 2021;2021:8880988. [PMID: 33628146 DOI: 10.1155/2021/8880988] [Reference Citation Analysis]
40 Boutron I, Ravaud P. Misrepresentation and distortion of research in biomedical literature. Proc Natl Acad Sci U S A 2018;115:2613-9. [PMID: 29531025 DOI: 10.1073/pnas.1710755115] [Cited by in Crossref: 81] [Cited by in F6Publishing: 47] [Article Influence: 27.0] [Reference Citation Analysis]
41 Lindholm D, Sarno G, Erlinge D, Svennblad B, Hasvold LP, Janzon M, Jernberg T, James SK. Combined association of key risk factors on ischaemic outcomes and bleeding in patients with myocardial infarction. Heart 2019;105:1175-81. [PMID: 31055499 DOI: 10.1136/heartjnl-2018-314590] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Bertoluci MC, Moreira RO, Faludi A, Izar MC, Schaan BD, Valerio CM, Bertolami MC, Chacra AP, Malachias MVB, Vencio S, Saraiva JFK, Betti R, Turatti L, Fonseca FAH, Bianco HT, Sulzbach M, Bertolami A, Salles JEN, Hohl A, Trujilho F, Lima EG, Miname MH, Zanella MT, Lamounier R, Sá JR, Amodeo C, Pires AC, Santos RD. Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM). Diabetol Metab Syndr 2017;9:53. [PMID: 28725272 DOI: 10.1186/s13098-017-0251-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
43 Ford I. Coming safely to a stop: a review of platelet activity after cessation of antiplatelet drugs. Ther Adv Drug Saf 2015;6:141-50. [PMID: 26301068 DOI: 10.1177/2042098615588085] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
44 Li X, Weber NC, Cohn DM, Hollmann MW, DeVries JH, Hermanides J, Preckel B. Effects of Hyperglycemia and Diabetes Mellitus on Coagulation and Hemostasis. J Clin Med 2021;10:2419. [PMID: 34072487 DOI: 10.3390/jcm10112419] [Reference Citation Analysis]
45 Yeh RW, Kereiakes DJ, Steg PG, Windecker S, Rinaldi MJ, Gershlick AH, Cutlip DE, Cohen DJ, Tanguay JF, Jacobs A, Wiviott SD, Massaro JM, Iancu AC, Mauri L; DAPT Study Investigators. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. J Am Coll Cardiol 2015;65:2211-21. [PMID: 25787199 DOI: 10.1016/j.jacc.2015.03.003] [Cited by in Crossref: 182] [Cited by in F6Publishing: 124] [Article Influence: 30.3] [Reference Citation Analysis]
46 Cho JY, Lee SY, Yun KH, Kim BK, Hong SJ, Ko JS, Rhee SJ, Oh SK, Shin DH, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y. Factors Related to Major Bleeding After Ticagrelor Therapy: Results from the TICO Trial. J Am Heart Assoc 2021;10:e019630. [PMID: 33739127 DOI: 10.1161/JAHA.120.019630] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Valgimigli M, Costa F, Lokhnygina Y, Clare RM, Wallentin L, Moliterno DJ, Armstrong PW, White HD, Held C, Aylward PE, Van de Werf F, Harrington RA, Mahaffey KW, Tricoci P. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J 2017;38:804-10. [PMID: 28363222 DOI: 10.1093/eurheartj/ehw525] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
48 Wang W, Wang X, Zhang L, Zhang J, Man F, Pan Q, Guo L. Treatment Outcomes of Clopidogrel in Patients With ACS and Diabetes Undergoing PCI-Analysis of Beijing Municipal Medical Insurance Database. Front Endocrinol (Lausanne) 2021;12:713849. [PMID: 34394007 DOI: 10.3389/fendo.2021.713849] [Reference Citation Analysis]
49 Reid C, Alturki A, Yan A, So D, Ko D, Tanguay JF, Bessissow A, Mehta S, Goodman S, Huynh T. Meta-analysis Comparing Outcomes of Type 2 Myocardial Infarction and Type 1 Myocardial Infarction With a Focus on Dual Antiplatelet Therapy. CJC Open 2020;2:118-28. [PMID: 32462125 DOI: 10.1016/j.cjco.2020.02.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Griffin MT, Zhu Y, Liu Z, Aidun CK, Ku DN. Inhibition of high shear arterial thrombosis by charged nanoparticles. Biomicrofluidics 2018;12:042210. [PMID: 29887934 DOI: 10.1063/1.5025349] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
51 Resor CD, Nathan A, Kereiakes DJ, Yeh RW, Massaro JM, Cutlip DE, Gabriel Steg P, Hsieh WH, Mauri L; Dual Antiplatelet Therapy Study Investigators. Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study. Circulation 2016;134:989-98. [PMID: 27576774 DOI: 10.1161/CIRCULATIONAHA.116.024531] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
52 Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014. Eur Heart J. 2015;36:3320-3331. [PMID: 26417060 DOI: 10.1093/eurheartj/ehv511] [Cited by in Crossref: 268] [Cited by in F6Publishing: 166] [Article Influence: 44.7] [Reference Citation Analysis]
53 Kinnaird T, Butt M, Abdul F, Yazji K, Hailan A, Gallagher S, Ossei-Gerning N, Chase A, Choudhury A, Smith D, Anderson R. Early Clinical Experience with a Polymer-Free Biolimus A9 Drug-Coated Stent in DES-Type Patients Who Are Poor Candidates for Prolonged Dual Anti-Platelet Therapy. PLoS One 2016;11:e0157812. [PMID: 27362841 DOI: 10.1371/journal.pone.0157812] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Cohen DJ, Steg PG, Cannon CP, Apruzzese PK, D'Agostino RB Sr, Massaro JM, Mauri L; Dual Antiplatelet Therapy (DAPT) Study Investigators. Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. JAMA Cardiol 2017;2:478-87. [PMID: 28297015 DOI: 10.1001/jamacardio.2017.0063] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
55 Chan Pin Yin D, Azzahhafi J, James S. Risk Assessment Using Risk Scores in Patients with Acute Coronary Syndrome. J Clin Med 2020;9:E3039. [PMID: 32967247 DOI: 10.3390/jcm9093039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
56 Bundhun PK, Yanamala CM, Huang F. Should a prolonged duration of dual anti-platelet therapy be recommended to patients with diabetes mellitus following percutaneous coronary intervention? A systematic review and meta-analysis of 15 studies. BMC Cardiovasc Disord 2016;16:161. [PMID: 27577530 DOI: 10.1186/s12872-016-0343-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
57 Su Y, Cheng X, Dong Q. Dual Antiplatelet Therapy of Clopidogrel and Aspirin in Secondary Prevention of Ischemic Stroke: Evidence and Indications. CNS Neurosci Ther 2015;21:870-6. [PMID: 26122554 DOI: 10.1111/cns.12419] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
58 Giustino G, Harari R, Baber U, Sartori S, Stone GW, Leon MB, Windecker S, Serruys PW, Kastrati A, Von Birgelen C, Kimura T, Stefanini GG, Dangas GD, Wijns W, Steg PG, Morice MC, Camenzind E, Weisz G, Smits PC, Sorrentino S, Sharma M, Farhan S, Faggioni M, Kandzari D, Galatius S, Jeger RV, Valgimigli M, Itchhaporia D, Mehta L, Kim HS, Chieffo A, Mehran R. Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JAMA Cardiol 2017;2:855-62. [PMID: 28658478 DOI: 10.1001/jamacardio.2017.1978] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
59 Navarese EP, Andreotti F, Schulze V, Kołodziejczak M, Buffon A, Brouwer M, Costa F, Kowalewski M, Parati G, Lip GY, Kelm M, Valgimigli M. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ 2015;350:h1618. [PMID: 25883067 DOI: 10.1136/bmj.h1618] [Cited by in Crossref: 216] [Cited by in F6Publishing: 154] [Article Influence: 36.0] [Reference Citation Analysis]
60 Cao D, Dangas G, Mehran R. Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction: Bleeding Avoidance First and Foremost. J Am Heart Assoc 2021;10:e019889. [PMID: 33559475 DOI: 10.1161/JAHA.120.019889] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Siddiqi OK, Smoot KJ, Dufour AB, Cho K, Young M, Gagnon DR, Ly S, Temiyasathit S, Faxon DP, Gaziano JM, Kinlay S. Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease. Heart 2015;101:1569-76. [PMID: 26209334 DOI: 10.1136/heartjnl-2014-307168] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
62 Yin SH, Xu P, Wang B, Lu Y, Wu QY, Zhou ML, Wu JR, Cai JJ, Sun X, Yuan H. Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis. BMJ 2019;365:l2222. [PMID: 31253632 DOI: 10.1136/bmj.l2222] [Cited by in Crossref: 41] [Cited by in F6Publishing: 23] [Article Influence: 20.5] [Reference Citation Analysis]
63 McDonald AI, Iruela-Arispe ML. Healing arterial ulcers: Endothelial lining regeneration upon vascular denudation injury. Vascul Pharmacol 2015;72:9-15. [PMID: 26093336 DOI: 10.1016/j.vph.2015.06.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
64 Blin P, Dureau-Pournin C, Lassalle R, Jové J, Thomas-Delecourt F, Droz-Perroteau C, Danchin N, Moore N. Outcomes in patients after myocardial infarction similar to those of the PEGASUS-TIMI 54 trial: A cohort study in the French national claims database. Br J Clin Pharmacol 2017;83:2056-65. [PMID: 28345154 DOI: 10.1111/bcp.13291] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
65 Tersalvi G, Biasco L, Cioffi GM, Pedrazzini G. Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective. J Clin Med 2020;9:E2064. [PMID: 32630233 DOI: 10.3390/jcm9072064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
66 Zlotnick DM, Canty JM Jr. Editorial Commentary: Striking a balance: Individualizing antithrombotic therapy after myocardial infarction. Trends Cardiovasc Med 2016;26:335-6. [PMID: 26522970 DOI: 10.1016/j.tcm.2015.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
67 Degrauwe S, Pilgrim T, Aminian A, Noble S, Meier P, Iglesias JF. Dual antiplatelet therapy for secondary prevention of coronary artery disease. Open Heart 2017;4:e000651. [PMID: 29081979 DOI: 10.1136/openhrt-2017-000651] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
68 Saito Y, Kobayashi Y. Update on Antithrombotic Therapy after Percutaneous Coronary Intervention.Intern Med. 2020;59:311-321. [PMID: 31588089 DOI: 10.2169/internalmedicine.3685-3719] [Reference Citation Analysis]
69 Zhu H, Xu X, Fang X, Ying F, Song L, Gao B, Tong G, Zhou L, Chen T, Huang J. Efficacy and Safety of Long-Term Antithrombotic Strategies in Patients With Chronic Coronary Syndrome: A Network Meta-analysis of Randomized Controlled Trials. J Am Heart Assoc 2021;10:e019184. [PMID: 33682435 DOI: 10.1161/JAHA.120.019184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Gulizia MM, Colivicchi F, Abrignani MG, Ambrosetti M, Aspromonte N, Barile G, Caporale R, Casolo G, Chiuini E, Di Lenarda A, Faggiano P, Gabrielli D, Geraci G, La Manna AG, Maggioni AP, Marchese A, Massari FM, Mureddu GF, Musumeci G, Nardi F, Panno AV, Pedretti RFE, Piredda M, Pusineri E, Riccio C, Rossini R, di Uccio FS, Urbinati S, Varbella F, Zito GB, De Luca L; ESC Scientific Document Group ., Faculty for approval of the Consensus Document . Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease. Eur Heart J Suppl 2018;20:F1-F74. [PMID: 29867293 DOI: 10.1093/eurheartj/suy019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 5.7] [Reference Citation Analysis]
71 Broeg-Morvay A, Mordasini P, Slezak A, Liesirova K, Meisterernst J, Schroth G, Arnold M, Jung S, Mattle HP, Gralla J, Fischer U. Does Antiplatelet Therapy during Bridging Thrombolysis Increase Rates of Intracerebral Hemorrhage in Stroke Patients? PLoS One 2017;12:e0170045. [PMID: 28095449 DOI: 10.1371/journal.pone.0170045] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
72 Doshi R, Vadher A, Mithawala P, Shah P. Oral antiplatelets in primary and secondary prevention of myocardial infarction: a review. Ir J Med Sci 2019;188:453-67. [PMID: 30178075 DOI: 10.1007/s11845-018-1897-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
73 Bruno A, Dovizio M, Tacconelli S, Contursi A, Ballerini P, Patrignani P. Antithrombotic Agents and Cancer. Cancers (Basel) 2018;10:E253. [PMID: 30065215 DOI: 10.3390/cancers10080253] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
74 Kubica J, Adamski P, Niezgoda P, Alexopoulos D, Badarienė J, Budaj A, Buszko K, Dudek D, Fabiszak T, Gąsior M, Gil R, Gorog DA, Grajek S, Gurbel PA, Gruchała M, Jaguszewski MJ, James S, Jeong YH, Jilma B, Kasprzak JD, Kleinrok A, Kubica A, Kuliczkowski W, Legutko J, Lesiak M, Siller-Matula JM, Nadolny K, Pstrągowski K, Di Somma S, Specchia G, Stępińska J, Tantry US, Tycińska A, Verdoia M, Wojakowski W, Navarese EP. Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. Cardiol J 2020;27:661-76. [PMID: 33073857 DOI: 10.5603/CJ.a2020.0132] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
75 Li J, Ju J, Chen Z, Liu J, Lu F, Gao R, Xu H. Guanxinning tablet for patients who switch from dual antiplatelet therapy to aspirin alone after percutaneous coronary intervention: study protocol for a cluster randomized controlled trial. Trials 2018;19:93. [PMID: 29415754 DOI: 10.1186/s13063-017-2373-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
76 Patti G, Cavallari I, Antonucci E, Calabrò P, Cirillo P, Gresele P, Palareti G, Pengo V, Pignatelli P, Ricottini E, Marcucci R. Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome. PLoS One 2017;12:e0186961. [PMID: 29059255 DOI: 10.1371/journal.pone.0186961] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
77 Zhang WJ, Qiao X, Guo WF, Liang XY, Li Y, Wang ZL. Duration of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome Treated With New Generation Stents: A Meta-Analysis of Randomized Controlled Trials. Front Cardiovasc Med 2021;8:615396. [PMID: 33614748 DOI: 10.3389/fcvm.2021.615396] [Reference Citation Analysis]
78 Tan JWC, Chew DP, Brieger D, Eikelboom J, Montalescot G, Ako J, Kim BK, Quek DK, Aitken SJ, Chow CK, Chour S, Tse HF, Kaul U, Firdaus I, Kubo T, Liew BW, Chong TT, Sin KY, Yeh HI, Buddhari W, Chunhamaneewat N, Hasan F, Fox KA, Nguyen QN, Lo ST. 2020 Asian Pacific Society of Cardiology Consensus Recommendations on Antithrombotic Management for High-risk Chronic Coronary Syndrome. Eur Cardiol 2021;16:e26. [PMID: 34249148 DOI: 10.15420/ecr.2020.45] [Reference Citation Analysis]
79 Stefanescu Schmidt AC, Kereiakes DJ, Cutlip DE, Yeh RW, D'Agostino RB Sr, Massaro JM, Hsieh WH, Mauri L; DAPT Investigators. Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). Circulation 2017;135:1720-32. [PMID: 28228427 DOI: 10.1161/CIRCULATIONAHA.116.024835] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
80 de la Torre Hernández JM, Edelman ER. From Nonclinical Research to Clinical Trials and Patient-registries: Challenges and Opportunities in Biomedical Research. Rev Esp Cardiol (Engl Ed) 2017;70:1121-33. [PMID: 28838647 DOI: 10.1016/j.rec.2017.07.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
81 Faridi KF, Tamez H, Butala NM, Song Y, Shen C, Secemsky EA, Mauri L, Curtis JP, Strom JB, Yeh RW. Comparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study: Findings From the EXTEND-DAPT Study. Circ Cardiovasc Qual Outcomes 2021;14:e006589. [PMID: 33435731 DOI: 10.1161/CIRCOUTCOMES.120.006589] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
82 Miyazaki Y, Suwannasom P, Sotomi Y, Abdelghani M, Tummala K, Katagiri Y, Asano T, Tenekecioglu E, Zeng Y, Cavalcante R, Collet C, Onuma Y, Serruys PW. Single or dual antiplatelet therapy after PCI. Nat Rev Cardiol 2017;14:294-303. [PMID: 28181585 DOI: 10.1038/nrcardio.2017.12] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 5.8] [Reference Citation Analysis]
83 Li Y, Jing Q, Wang B, Wang X, Li J, Qiao S, Chen S, Angiolillo DJ, Han Y. Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial. Am Heart J 2020;228:1-7. [PMID: 32739652 DOI: 10.1016/j.ahj.2020.07.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
84 Hara T, Ughi GJ, McCarthy JR, Erdem SS, Mauskapf A, Lyon SC, Fard AM, Edelman ER, Tearney GJ, Jaffer FA. Intravascular fibrin molecular imaging improves the detection of unhealed stents assessed by optical coherence tomography in vivo. Eur Heart J 2017;38:447-55. [PMID: 26685129 DOI: 10.1093/eurheartj/ehv677] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
85 Cannon CP, Gropper S, Bhatt DL, Ellis SG, Kimura T, Lip GY, Steg PG, Ten Berg JM, Manassie J, Kreuzer J, Blatchford J, Massaro JM, Brueckmann M, Ferreiros Ripoll E, Oldgren J, Hohnloser SH; RE-DUAL PCI Steering Committee and Investigators. Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. Clin Cardiol 2016;39:555-64. [PMID: 27565018 DOI: 10.1002/clc.22572] [Cited by in Crossref: 57] [Cited by in F6Publishing: 36] [Article Influence: 11.4] [Reference Citation Analysis]
86 Tsoi MF, Cheung CL, Cheung TT, Wong IC, Kumana CR, Tse HF, Cheung BM. Duration of dual antiplatelet therapy after drug-eluting stent implantation: Meta-analysis of large randomised controlled trials. Sci Rep 2015;5:13204. [PMID: 26278959 DOI: 10.1038/srep13204] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
87 Pasea L, Chung SC, Pujades-Rodriguez M, Moayyeri A, Denaxas S, Fox KAA, Wallentin L, Pocock SJ, Timmis A, Banerjee A, Patel R, Hemingway H. Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors. Eur Heart J 2017;38:1048-55. [PMID: 28329300 DOI: 10.1093/eurheartj/ehw683] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 7.5] [Reference Citation Analysis]
88 Yeh RW, Mauri L, Kereiakes DJ. Dual Antiplatelet Therapy Duration Following Coronary Stenting. [Corrected]. J Am Coll Cardiol 2015;65:787-90. [PMID: 25720621 DOI: 10.1016/j.jacc.2015.01.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
89 Chaturvedula S, Diver D, Vashist A. Antiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma. J Clin Med 2018;7:E74. [PMID: 29642547 DOI: 10.3390/jcm7040074] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
90 Ostrowska M, Kubica J, Adamski P, Kubica A, Eyileten C, Postula M, Toma A, Hengstenberg C, Siller-Matula JM. Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing. Front Cardiovasc Med 2019;6:176. [PMID: 31850373 DOI: 10.3389/fcvm.2019.00176] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
91 Thukkani AK, Agrawal K, Prince L, Smoot KJ, Dufour AB, Cho K, Gagnon DR, Sokolovskaya G, Ly S, Temiyasathit S, Faxon DP, Gaziano JM, Kinlay S. Long-Term Outcomes in Patients With Diabetes Mellitus Related to Prolonging Clopidogrel More Than 12 Months After Coronary Stenting. J Am Coll Cardiol 2015;66:1091-101. [PMID: 26337986 DOI: 10.1016/j.jacc.2015.06.1339] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
92 Xulu KR, Augustine TN. Antiplatelet Therapy Combined with Anastrozole Induces Features of Partial EMT in Breast Cancer Cells and Fails to Mitigate Breast-Cancer Induced Hypercoagulation. Int J Mol Sci 2021;22:4153. [PMID: 33923802 DOI: 10.3390/ijms22084153] [Reference Citation Analysis]
93 Verdoia M, Camaro C, Kedhi E, Marcolongo M, Suryapranata H, De Luca G. Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues. Cardiovasc Ther 2020;2020:6495036. [PMID: 32328172 DOI: 10.1155/2020/6495036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
94 Chang TI, Montez-Rath ME, Tsai TT, Hlatky MA, Winkelmayer WC. Drug-Eluting Versus Bare-Metal Stents During PCI in Patients With End-Stage Renal Disease on Dialysis. J Am Coll Cardiol 2016;67:1459-69. [PMID: 27012407 DOI: 10.1016/j.jacc.2015.10.104] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
95 Lohaus R, Michel J, Mayer K, Lahmann AL, Byrne RA, Wolk A, Ten Berg JM, Neumann FJ, Han Y, Adriaenssens T, Tölg R, Seyfarth M, Maeng M, Zrenner B, Jacobshagen C, Wöhrle J, Kufner S, Morath T, Ibrahim T, Bernlochner I, Fischer M, Schunkert H, Laugwitz KL, Mehilli J, Kastrati A, Schulz-Schüpke S. Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis. Sci Rep 2016;6:33054. [PMID: 27624287 DOI: 10.1038/srep33054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
96 Fanari Z, Malodiya A, Weiss SA, Hammami S, Kolm P, Weintraub WS. Long-term use of dual antiplatelet therapy for the secondary prevention of atherothrombotic events: Meta-analysis of randomized controlled trials. Cardiovasc Revasc Med 2017;18:10-5. [PMID: 27477306 DOI: 10.1016/j.carrev.2016.07.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.6] [Reference Citation Analysis]
97 Lee JM, Jung JH, Park KW, Shin ES, Oh SK, Bae JW, Rhew JY, Lee N, Kim DB, Kim U, Han JK, Lee SE, Yang HM, Kang HJ, Koo BK, Kim S, Cho YK, Shin WY, Lim YH, Rha SW, Kim SY, Lee SY, Kim YD, Chae IH, Cha KS, Kim HS. Harmonizing Optimal Strategy for Treatment of coronary artery diseases--comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial. Trials 2015;16:409. [PMID: 26374625 DOI: 10.1186/s13063-015-0925-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
98 Palmerini T, Della Riva D, Benedetto U, Bacchi Reggiani L, Feres F, Abizaid A, Gilard M, Morice MC, Valgimigli M, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Colombo A, Chieffo A, Sangiorgi D, Biondi-Zoccai G, Généreux P, Angelini GD, Pufulete M, White J, Bhatt DL, Stone GW. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. Eur Heart J 2017;38:1034-43. [PMID: 28110296 DOI: 10.1093/eurheartj/ehw627] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
99 Habib A, Finn AV. Endothelialization of drug eluting stents and its impact on dual anti-platelet therapy duration. Pharmacol Res 2015;93:22-7. [PMID: 25533811 DOI: 10.1016/j.phrs.2014.12.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
100 Butala NM, Faridi KF, Secemsky EA, Song Y, Curtis J, Gibson CM, Kazi D, Shen C, Yeh RW. Prognosis of Claims- Versus Trial-Based Ischemic and Bleeding Events Beyond 1 Year After Coronary Stenting. J Am Heart Assoc 2021;10:e018744. [PMID: 33682431 DOI: 10.1161/JAHA.120.018744] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
101 Costa F, Ariotti S, Valgimigli M, Kolh P, Windecker S; Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Perspectives on the 2014 ESC/EACTS Guidelines on Myocardial Revascularization : Fifty Years of Revascularization: Where Are We and Where Are We Heading? J Cardiovasc Transl Res 2015;8:211-20. [PMID: 25986910 DOI: 10.1007/s12265-015-9632-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
102 Frere C, Lejeune M, Kubicek P, Faille D, Marjanovic Z; Groupe Francophone Thrombose et Cancer. Antiplatelet Agents for Cancer Prevention: Current Evidences and Continuing Controversies. Cancers (Basel) 2019;11:E1639. [PMID: 31653027 DOI: 10.3390/cancers11111639] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
103 Li H, Guo W, Dai W, Li L. Short-versus long-term dual antiplatelet therapy after second-generation drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther 2018;12:1815-25. [PMID: 29970956 DOI: 10.2147/DDDT.S165435] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
104 Fanari Z, Weiss S, Weintraub WS. Cost Effectiveness of Antiplatelet and Antithrombotic Therapy in the Setting of Acute Coronary Syndrome: Current Perspective and Literature Review. Am J Cardiovasc Drugs 2015;15:415-27. [PMID: 26068886 DOI: 10.1007/s40256-015-0131-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
105 Alfredsson J, Roe MT. Risks and benefits of triple oral anti-thrombotic therapies after acute coronary syndromes and percutaneous coronary intervention. Drug Saf. 2015;38:481-491. [PMID: 25829216 DOI: 10.1007/s40264-015-0286-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
106 Kandan SR, Johnson TW. Contemporary Antiplatelet Strategies in the Treatment of STEMI using Primary Percutaneous Coronary Intervention. Interv Cardiol 2015;10:26-31. [PMID: 29588670 DOI: 10.15420/icr.2015.10.1.26] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
107 Simon N, Finzi J, Cayla G, Montalescot G, Collet JP, Hulot JS. Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients. Eur J Clin Pharmacol 2015;71:1059-66. [PMID: 26071277 DOI: 10.1007/s00228-015-1882-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
108 Toyota T, Shiomi H, Morimoto T, Natsuaki M, Kimura T. Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: A comparison between the DAPT study and 9 other trials evaluating DAPT duration. PLoS One 2017;12:e0174502. [PMID: 28931015 DOI: 10.1371/journal.pone.0174502] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
109 Park SD, Moon J, Kwon SW, Suh YJ, Kim TH, Jang HJ, Suh J, Park HW, Oh PC, Shin SH, Woo SI, Kim DH, Kwan J, Kang W. Prognostic Impact of Combined Contrast-Induced Acute Kidney Injury and Hypoxic Liver Injury in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results from INTERSTELLAR Registry. PLoS One 2016;11:e0159416. [PMID: 27415006 DOI: 10.1371/journal.pone.0159416] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
110 Cho MS, Park DW. Stent thrombosis and optimal duration of dual antiplatelet therapy after coronary stenting in contemporary practice. Korean J Intern Med 2017;32:769-79. [PMID: 28823143 DOI: 10.3904/kjim.2016.391] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
111 Kim DY, Cho SW, Park KT, Ahn JH, Park TK, Jang YH, Choi KH, Lee JM, Yang JH, Song YB, Choi JH, Choi SH, Gwon HC, Lee SH, Hahn JY. Long-term Outcomes of Clopidogrel Monotherapy versus Prolonged Dual Antiplatelet Therapy beyond 12 Months after Percutaneous Coronary Intervention in High-risk Patients. J Korean Med Sci 2021;36:e106. [PMID: 33904262 DOI: 10.3346/jkms.2021.36.e106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Johansson S, Rosengren A, Young K, Jennings E. Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review. BMC Cardiovasc Disord 2017;17:53. [PMID: 28173750 DOI: 10.1186/s12872-017-0482-9] [Cited by in Crossref: 75] [Cited by in F6Publishing: 58] [Article Influence: 18.8] [Reference Citation Analysis]
113 Pasalic L, Wing-Lun E, Lau JK, Campbell H, Pennings GJ, Lau E, Connor D, Liang HP, Muller D, Kritharides L, Hogg PJ, Chen VM. Novel assay demonstrates that coronary artery disease patients have heightened procoagulant platelet response. J Thromb Haemost 2018;16:1198-210. [PMID: 29569428 DOI: 10.1111/jth.14008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
114 Krackhardt F, Kočka V, Waliszewski MW, Utech A, Lustermann M, Hudec M, Studenčan M, Schwefer M, Yu J, Jeong MH, Ahn T, Wan Ahmad WA, Boxberger M, Schneider A, Leschke M. Polymer-free sirolimus-eluting stents in a large-scale all-comers population. Open Heart 2017;4:e000592. [PMID: 28761678 DOI: 10.1136/openhrt-2017-000592] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
115 Faridi KF, Tamez H, Strom JB, Song Y, Butala NM, Shen C, Secemsky EA, Mauri L, Curtis JP, Gibson CM, Yeh RW. Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND-DAPT Study. Circulation 2020;142:306-8. [PMID: 32687440 DOI: 10.1161/CIRCULATIONAHA.120.047729] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
116 Mavrakanas TA, Chatzizisis YS, Gariani K, Kereiakes DJ, Gargiulo G, Helft G, Gilard M, Feres F, Costa RA, Morice MC, Georges JL, Valgimigli M, Bhatt DL, Mauri L, Charytan DM. Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents: A Meta-Analysis. Clin J Am Soc Nephrol 2019;14:810-22. [PMID: 31010936 DOI: 10.2215/CJN.12901018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
117 Sharp MK, Haneef R, Ravaud P, Boutron I. Dissemination of 2014 dual antiplatelet therapy (DAPT) trial results: a systematic review of scholarly and media attention over 7 months. BMJ Open 2017;7:e014503. [PMID: 29101129 DOI: 10.1136/bmjopen-2016-014503] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
118 Bradley SM, Hess GP, Stewart P, Armstrong EJ, Farmer SA, Wasfy JH, Valle JA, Sandhu A, Maddox TM. Implications of the PEGASUS-TIMI 54 trial for US clinical practice. Open Heart 2017;4:e000580. [PMID: 28674626 DOI: 10.1136/openhrt-2016-000580] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
119 Cordonnier C, Lemesle G, Casolla B, Bic M, Caparros F, Lamblin N, Bauters C. Incidence and determinants of cerebrovascular events in outpatients with stable coronary artery disease. Eur Stroke J 2018;3:272-80. [PMID: 31008358 DOI: 10.1177/2396987318772684] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
120 Shimamatsu J, Sasaki KI, Katsuki Y, Kawasaki T, Murasato Y, Ajisaka H, Yokoi H, Tashiro H, Harada A, Hirakawa Y, Ishizaki Y, Ishimatsu T, Kagiyama K, Fukumoto Y, Kakuma T, Ueno T. Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation. Heart Vessels 2020;35:312-22. [PMID: 31549178 DOI: 10.1007/s00380-019-01499-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
121 Sanchez F, Boasi V, Vercellino M, Tacchi C, Cannarile P, Pingelli N, Perri D, Gomez L, Cattunar S, Mascelli G. Risk definition and outcomes with the application of the PEGASUS-TIMI 54 trial inclusion criteria to a "real world" STEMI population: results from the Italian "CARDIO-STEMI SANREMO" registry. BMC Cardiovasc Disord 2021;21:144. [PMID: 33736607 DOI: 10.1186/s12872-020-01780-y] [Reference Citation Analysis]
122 Mauri L, Elmariah S, Yeh RW, Cutlip DE, Steg PG, Windecker S, Wiviott SD, Cohen DJ, Massaro JM, D'Agostino RB Sr, Braunwald E, Kereiakes DJ; DAPT Study Investigators. Causes of late mortality with dual antiplatelet therapy after coronary stents. Eur Heart J 2016;37:378-85. [PMID: 26586780 DOI: 10.1093/eurheartj/ehv614] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
123 Borges LF, Robertson JM, Kappler SM, Venkatan SK, Jin DX, Barnes EL, Jaffer FA, Saldana FL, Dudzinski DM, Stefanescu Schmidt AC, Drachman DE, Young MN, Hayden EM, Pelletier SR, Shields HM. Optimizing Multidisciplinary Simulation in Medical School for Larger Groups: Role Assignment by Lottery and Guided Learning. Adv Med Educ Pract 2020;11:969-76. [PMID: 33376436 DOI: 10.2147/AMEP.S270272] [Reference Citation Analysis]
124 Jiang M, You JHS. Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome. Clin Cardiol 2017;40:789-96. [PMID: 28683175 DOI: 10.1002/clc.22756] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
125 Lenihan DJ, Fradley MG, Dent S, Brezden-Masley C, Carver J, Filho RK, Neilan TG, Blaes A, Melloni C, Herrmann J, Armenian S, Thavendiranathan P, Armstrong GT, Ky B, Hajjar L. Proceedings From the Global Cardio-Oncology Summit: The Top 10 Priorities to Actualize for CardioOncology. JACC CardioOncol 2019;1:256-72. [PMID: 34396188 DOI: 10.1016/j.jaccao.2019.11.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
126 Karimi Galougahi K, Karmpaliotis D, Kirtane AJ, Ali ZA. Shedding blood: anemia and adverse events after percutaneous coronary intervention (PCI). J Thorac Dis 2016;8:303-6. [PMID: 27076922 DOI: 10.21037/jtd.2016.02.29] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
127 Rossello X, Bueno H, Pocock SJ, Van de Werf F, Danchin N, Annemans L, Medina J, Zeymer U. Predictors of all-cause mortality and ischemic events within and beyond 1 year after an acute coronary syndrome: Results from the EPICOR registry. Clin Cardiol 2019;42:111-9. [PMID: 30443916 DOI: 10.1002/clc.23116] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
128 Lin TT, Lai HY, Chan KA, Yang YY, Lai CL, Lai MS. Single and dual antiplatelet therapy in elderly patients of medically managed myocardial infarction. BMC Geriatr 2018;18:86. [PMID: 29621983 DOI: 10.1186/s12877-018-0777-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
129 Kang J, Kim HS. The Evolving Concept of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: Focus on Unique Feature of East Asian and "Asian Paradox". Korean Circ J 2018;48:537-51. [PMID: 29968428 DOI: 10.4070/kcj.2018.0166] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 7.7] [Reference Citation Analysis]
130 Villablanca PA, Massera D, Mathew V, Bangalore S, Christia P, Perez I, Wan N, Schulz-Schüpke S, Briceno DF, Bortnick AE, Garcia MJ, Lucariello R, Menegus M, Pyo R, Wiley J, Ramakrishna H. Outcomes of ≤6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation: A meta-analysis and meta-regression. Medicine (Baltimore) 2016;95:e5819. [PMID: 28033306 DOI: 10.1097/MD.0000000000005819] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
131 Westermann D, Goodman SG, Nicolau JC, Requena G, Maguire A, Chen JY, Granger CB, Grieve R, Pocock SJ, Blankenberg S, Vega AM, Yasuda S, Simon T, Brieger D; TIGRIS Study Investigators. Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study. Clin Cardiol 2017;40:1197-204. [PMID: 29247524 DOI: 10.1002/clc.22837] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
132 Yang H, Zhang F, Yang J, Zheng M, Cao R, Dai Y, Li C, Yao K, Qian J, Ge J; TARGET DAPT trial investigators. Prospective multicentre open-label randomised controlled trial of 3-month versus 12-month dual antiplatelet therapy after implantation of the new generation biodegradable polymer sirolimus TARGET-eluting coronary stent: protocol of the TARGET DAPT trial. BMJ Open 2019;9:e033774. [PMID: 31852711 DOI: 10.1136/bmjopen-2019-033774] [Reference Citation Analysis]
133 Halim H, Pinkaew D, Chunhacha P, Sinthujaroen P, Thiagarajan P, Fujise K. Ticagrelor induces paraoxonase-1 (PON1) and better protects hypercholesterolemic mice against atherosclerosis compared to clopidogrel. PLoS One 2019;14:e0218934. [PMID: 31242230 DOI: 10.1371/journal.pone.0218934] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
134 Verdoia M, Suryapranata H, Damen S, Camaro C, Benit E, Barbieri L, Rasoul S, Liew HB, Polad J, Ahmad WAW, Zambahari R, Lalmand J, van der Schaaf RJ, Koh TH, Timmermans P Sr, Dilling-Boer D, Veenstra LF, Van't Hof AWJ, Lee SWL, Roolvink V, Ligtenberg E, Postma S, Kolkman EJJ, Brouwer MA, Kedhi E, De Luca G. Gender differences with short-term vs 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE trial. J Thromb Thrombolysis 2021. [PMID: 33847862 DOI: 10.1007/s11239-021-02439-x] [Reference Citation Analysis]
135 Cohen M. Long-term outcomes in high-risk patients with non-ST-segment elevation myocardial infarction. J Thromb Thrombolysis 2016;41:464-74. [PMID: 26001907 DOI: 10.1007/s11239-015-1227-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
136 Covic A, Genovesi S, Rossignol P, Kalra PA, Ortiz A, Banach M, Burlacu A. Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations. BMC Med 2018;16:158. [PMID: 30227855 DOI: 10.1186/s12916-018-1145-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
137 Pei C, Zhang Y, Wang P, Zhang B, Fang L, Liu B, Meng S. Berberine alleviates oxidized low-density lipoprotein-induced macrophage activation by downregulating galectin-3 via the NF-κB and AMPK signaling pathways. Phytother Res 2019;33:294-308. [PMID: 30402951 DOI: 10.1002/ptr.6217] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
138 Arahata M, Asakura H. Antithrombotic therapies for elderly patients: handling problems originating from their comorbidities. Clin Interv Aging 2018;13:1675-90. [PMID: 30237704 DOI: 10.2147/CIA.S174896] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
139 Polo Friz H, Molteni M, Cimminiello C. The dogma of aspirin: a critical review of evidence on the best monotherapy after dual antiplatelet therapy. Thromb J 2015;13:28. [PMID: 26347594 DOI: 10.1186/s12959-015-0059-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
140 Helft G. Dual antiplatelet therapy duration after drug-eluting stents: how long? J Thorac Dis 2016;8:E844-6. [PMID: 27620368 DOI: 10.21037/jtd.2016.07.45] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
141 Bravo PE, Di Carli MF. Does clopidogrel affect the efficacy of myocardial perfusion imaging? J Nucl Cardiol 2016;23:780-2. [PMID: 26338430 DOI: 10.1007/s12350-015-0280-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
142 Kim CH, Han JK, Yang HM, Park KW, Lee HY, Kang HJ, Koo BK, Lee N, Cha TJ, Yang TH, Jeong MH, Yoon MH, Lee SU, Lee SJ, Kim JW, Cho JM, Han KR, Pyun WB, Kim HS. Study protocol for a randomised controlled trial: harmonising optimal strategy for treatment of coronary artery stenosis - coronary intervention with next-generation drug-eluting stent platforms and abbreviated dual antiplatelet therapy (HOST-IDEA) trial. BMJ Open 2017;7:e016617. [PMID: 29025834 DOI: 10.1136/bmjopen-2017-016617] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
143 Watanabe H, Morimoto T, Natsuaki M, Furukawa Y, Nakagawa Y, Kadota K, Yamaji K, Ando K, Shizuta S, Shiomi H, Tada T, Tazaki J, Kato Y, Hayano M, Abe M, Tamura T, Shirotani M, Miki S, Matsuda M, Takahashi M, Ishii K, Tanaka M, Aoyama T, Doi O, Hattori R, Kato M, Suwa S, Takizawa A, Takatsu Y, Shinoda E, Eizawa H, Takeda T, Lee JD, Inoko M, Ogawa H, Hamasaki S, Horie M, Nohara R, Kambara H, Fujiwara H, Mitsudo K, Nobuyoshi M, Kita T, Kastrati A, Kimura T; CREDO-Kyoto PCI/CABG registry cohort-2 investigators. Antiplatelet therapy discontinuation and the risk of serious cardiovascular events after coronary stenting: observations from the CREDO-Kyoto Registry Cohort-2. PLoS One 2015;10:e0124314. [PMID: 25853836 DOI: 10.1371/journal.pone.0124314] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
144 Strom JB, Tamez H, Zhao Y, Valsdottir LR, Curtis J, Brennan JM, Shen C, Popma JJ, Mauri L, Yeh RW. Validating the use of registries and claims data to support randomized trials: Rationale and design of the Extending Trial-Based Evaluations of Medical Therapies Using Novel Sources of Data (EXTEND) Study. Am Heart J 2019;212:64-71. [PMID: 30953936 DOI: 10.1016/j.ahj.2019.02.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
145 Vogel B, Baber U, Cohen DJ, Sartori S, Sharma SK, Angiolillo DJ, Farhan S, Goel R, Zhang Z, Briguori C, Collier T, Dangas G, Dudek D, Escaned J, Gil R, Han YL, Kaul U, Kornowski R, Krucoff MW, Kunadian V, Mehta SR, Moliterno D, Ohman EM, Sardella G, Witzenbichler B, Gibson CM, Pocock S, Huber K, Mehran R. Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial. JAMA Cardiol 2021. [PMID: 33991416 DOI: 10.1001/jamacardio.2021.1720] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
146 Horne BD, Muhlestein JB, Bhandary D, Hoetzer GL, Khan ND, Bair TL, Lappé DL. Clinically feasible stratification of 1-year to 3-year post-myocardial infarction risk. Open Heart 2018;5:e000723. [PMID: 29531761 DOI: 10.1136/openhrt-2017-000723] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
147 Gupta S. Very very late stent thrombosis: 9.5 years after DES implantation. Indian Heart J 2016;68 Suppl 2:S39-43. [PMID: 27751323 DOI: 10.1016/j.ihj.2016.01.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
148 Pedroza C, Tyson JE, Das A, Laptook A, Bell EF, Shankaran S; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Advantages of Bayesian monitoring methods in deciding whether and when to stop a clinical trial: an example of a neonatal cooling trial. Trials 2016;17:335. [PMID: 27450203 DOI: 10.1186/s13063-016-1480-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
149 Natsuaki M, Morimoto T, Yamamoto E, Shiomi H, Furukawa Y, Abe M, Nakao K, Ishikawa T, Kawai K, Yunoki K, Shimizu S, Akao M, Miki S, Yamamoto M, Okada H, Hoshino K, Kadota K, Morino Y, Igarashi K, Tanabe K, Kozuma K, Kimura T. One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial. Cardiovasc Interv Ther 2016;31:196-209. [PMID: 26518420 DOI: 10.1007/s12928-015-0366-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
150 Grodzinsky A, Arnold SV, Wang TY, Sharma P, Gosch K, Jones PG, Bhatt DL, Steg PG, McGuire DK, Cohen DJ, Spertus JA, Chhatriwalla AK, Lind M, Graham G, Kosiborod M. Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy. Am Heart J 2016;182:111-8. [PMID: 27914490 DOI: 10.1016/j.ahj.2016.09.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
151 Braun A, Anders HJ, Gudermann T, Mammadova-Bach E. Platelet-Cancer Interplay: Molecular Mechanisms and New Therapeutic Avenues. Front Oncol 2021;11:665534. [PMID: 34322381 DOI: 10.3389/fonc.2021.665534] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
152 Patti G, Cavallari I, Andreotti F, Calabrò P, Cirillo P, Denas G, Galli M, Golia E, Maddaloni E, Marcucci R, Parato VM, Pengo V, Prisco D, Ricottini E, Renda G, Santilli F, Simeone P, De Caterina R; Working Group on Thrombosis of the Italian Society of Cardiology. Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. Nat Rev Cardiol 2019;16:113-30. [PMID: 30250166 DOI: 10.1038/s41569-018-0080-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 30.0] [Reference Citation Analysis]
153 Mathews R, Wang TY, Honeycutt E, Henry TD, Zettler M, Chang M, Fonarow GC, Peterson ED; TRANSLATE-ACS Study Investigators. Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study. Am Heart J 2015;170:62-9. [PMID: 26093865 DOI: 10.1016/j.ahj.2015.03.019] [Cited by in Crossref: 79] [Cited by in F6Publishing: 59] [Article Influence: 13.2] [Reference Citation Analysis]
154 Bularga A, Meah MN, Doudesis D, Shah ASV, Mills NL, Newby DE, Lee KK. Duration of dual antiplatelet therapy and stability of coronary heart disease: a 60 000-patient meta-analysis of randomised controlled trials. Open Heart 2021;8:e001707. [PMID: 34341097 DOI: 10.1136/openhrt-2021-001707] [Reference Citation Analysis]
155 Gray A, McQuillan C, Menown IBA. Advances in Clinical Cardiology 2016: A Summary of the Key Clinical Trials. Adv Ther 2017;34:1503-27. [PMID: 28537000 DOI: 10.1007/s12325-017-0560-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
156 Ariotti S, Gargiulo G, Valgimigli M. Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease. Curr Cardiol Rep. 2017;19:2. [PMID: 28097533 DOI: 10.1007/s11886-017-0810-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
157 Lu R, Tang F, Zhang Y, Zhu X, Zhu S, Wang G, Jiang Y, Fan Z. Comparison of Drug-Eluting and Bare Metal Stents in Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta-Analysis. J Am Heart Assoc 2016;5:e003990. [PMID: 27821401 DOI: 10.1161/JAHA.116.003990] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
158 Wilson SJ, Newby DE, Dawson D, Irving J, Berry C. Duration of dual antiplatelet therapy in acute coronary syndrome. Heart 2017;103:573-80. [PMID: 28249994 DOI: 10.1136/heartjnl-2016-309871] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
159 Feng WH, Hsieh IC, Li YH. P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: Is It Safe to Abandon Aspirin? Acta Cardiol Sin 2021;37:1-8. [PMID: 33488022 DOI: 10.6515/ACS.202101_37(1).20200806A] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
160 Karimi M, Zare H, Bakhshian Nik A, Yazdani N, Hamrang M, Mohamed E, Sahandi Zangabad P, Moosavi Basri SM, Bakhtiari L, Hamblin MR. Nanotechnology in diagnosis and treatment of coronary artery disease. Nanomedicine (Lond) 2016;11:513-30. [PMID: 26906471 DOI: 10.2217/nnm.16.3] [Cited by in Crossref: 40] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
161 Strom JB, Faridi KF, Butala NM, Zhao Y, Tamez H, Valsdottir LR, Brennan JM, Shen C, Popma JJ, Kazi DS, Yeh RW. Use of Administrative Claims to Assess Outcomes and Treatment Effect in Randomized Clinical Trials for Transcatheter Aortic Valve Replacement: Findings From the EXTEND Study. Circulation 2020;142:203-13. [PMID: 32436390 DOI: 10.1161/CIRCULATIONAHA.120.046159] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
162 Saito Y, Kobayashi Y. Update on Antithrombotic Therapy after Percutaneous Coronary Intervention. Intern Med 2020;59:311-21. [PMID: 31588089 DOI: 10.2169/internalmedicine.3685-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
163 Park HS, Kim YH, Kim JS, Oh YS, Shin DG, Pak HN, Hwang GS, Choi KJ, Oh S, Kim JB, Lee MY, Park HW, Kim DK, Jin ES, Park JS, Oh IY, Shin DH, Park HS, Kim JH, Kim NH, Ahn MS, Seo BJ, Kim YJ, Kang S, Lee J. Status of international normalized ratio control and treatment patterns in patients with nonvalvular atrial fibrillation taking vitamin K antagonist with or without antiplatelet therapy: Results from KORAFII registry. J Arrhythm 2019;35:593-601. [PMID: 31410229 DOI: 10.1002/joa3.12183] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
164 Lam DH, Bell SM, Hira RS. Concomitant Use of Antiplatelets and Anticoagulants in Patients with Coronary Heart Disease and Atrial Fibrillation: What Do Recent Clinical Trials Teach Us? Curr Atheroscler Rep 2018;20:4. [PMID: 29349596 DOI: 10.1007/s11883-018-0703-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
165 Yang J, Fan ZX, Yang CJ, Wang HB. A Meta-Analysis of Randomized Clinical Trials Comparing Shorter (Less or Equal Than 6 Months) and Longer (More or Equal Than 12 Months) Dual Anti-Platelet Therapy Following Drug-Eluting Coronary Stents. Iran Red Crescent Med J 2015;17:e26904. [PMID: 26421177 DOI: 10.5812/ircmj.26904] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
166 Berg DD, Yeh RW, Mauri L, Morrow DA, Kereiakes DJ, Cutlip DE, Gao Q, Jarolim P, Michelson AD, Frelinger AL 3rd, Cange AL, Sabatine MS, O'Donoghue ML. Biomarkers of platelet activation and cardiovascular risk in the DAPT trial. J Thromb Thrombolysis 2021;51:675-81. [PMID: 32683645 DOI: 10.1007/s11239-020-02221-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
167 Fleming TR, Ellenberg SS, DeMets DL. Data Monitoring Committees: Current issues. Clin Trials 2018;15:321-8. [PMID: 29629815 DOI: 10.1177/1740774518764855] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
168 Vos GJ, Bennaghmouch N, Qaderdan K, Ten Berg JM. Management of the patient with an acute coronary syndrome using oral anticoagulation. Neth Heart J 2015;23:407-14. [PMID: 26184420 DOI: 10.1007/s12471-015-0727-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
169 Floyd CN. Dual Antiplatelet Therapy in Coronary Artery Disease: Comparison Between ACC/AHA 2016 and ESC 2017 Guidelines. Eur Cardiol 2020;15:1-3. [PMID: 32180836 DOI: 10.15420/ecr.2019.09] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
170 Davenport ED, Syburra T, Gray G, Rienks R, Bron D, Manen O, d'Arcy J, Guettler NJ, Nicol ED. Management of established coronary artery disease in aircrew with previous myocardial infarction or revascularisation. Heart 2019;105:s31-7. [PMID: 30425084 DOI: 10.1136/heartjnl-2018-313055] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
171 Ibrahim W, Mohamed A, Sheikh M, Shokr M, Hassan A, Wienberger J, Afonso LC. Antiplatelet Therapy and Spontaneous Retroperitoneal Hematoma: A Case Report and Literature Review. Am J Case Rep. 2017;18:85-89. [PMID: 28119516 DOI: 10.12659/ajcr.901622] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.8] [Reference Citation Analysis]
172 Lee OH, Kim BK, Hong SJ, Kim S, Ahn CM, Shin DH, Kim JS, Kang TS, Ko YG, Choi D, Hong MK, Jang Y. Determinants and Clinical Outcomes of Extended Dual Antiplatelet Therapy over 3 Years after Drug-Eluting Stent Implantation: A Retrospective Analysis. Yonsei Med J 2020;61:597-605. [PMID: 32608203 DOI: 10.3349/ymj.2020.61.7.597] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
173 Sorbets E, Steg PG. Direct-acting Anticoagulants in Chronic Coronary Syndromes. Eur Cardiol 2020;15:1-7. [PMID: 32180831 DOI: 10.15420/ecr.2018.24.2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
174 Merinopoulos I, Gunawardena T, Wickramarachchi U, Ryding A, Eccleshall S, Vassiliou VS. Percutaneous Coronary Intervention in the Elderly: Are Drug-coated Balloons the Future? Curr Cardiol Rev 2018;14:45-52. [PMID: 29278215 DOI: 10.2174/1573403X14666171226144120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
175 Waldron NH, Dallas T, Erhunmwunsee L, Wang TY, Berry MF, Welsby IJ. Bleeding risk associated with eptifibatide (Integrilin) bridging in thoracic surgery patients. J Thromb Thrombolysis 2017;43:194-202. [PMID: 27798792 DOI: 10.1007/s11239-016-1441-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
176 Costa F, Tijssen JG, Ariotti S, Giatti S, Moscarella E, Guastaroba P, De Palma R, Andò G, Oreto G, Zijlstra F, Valgimigli M. Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy. J Am Heart Assoc 2015;4:e002524. [PMID: 26643501 DOI: 10.1161/JAHA.115.002524] [Cited by in Crossref: 33] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
177 Kotecha T, Rakhit RD. Acute coronary syndromes. Clin Med (Lond) 2016;16:s43-8. [PMID: 27956440 DOI: 10.7861/clinmedicine.16-6-s43] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
178 Natsuaki M, Morimoto T, Yamaji K, Watanabe H, Yoshikawa Y, Shiomi H, Nakagawa Y, Furukawa Y, Kadota K, Ando K, Akasaka T, Hanaoka KI, Kozuma K, Tanabe K, Morino Y, Muramatsu T, Kimura T; CREDO‐Kyoto PCI/CABG Registry Cohort 2, RESET, and NEXT trial investigators. Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO-Kyoto Thrombotic and Bleeding Risk Scores. J Am Heart Assoc 2018;7:e008708. [PMID: 29789335 DOI: 10.1161/JAHA.118.008708] [Cited by in Crossref: 55] [Cited by in F6Publishing: 8] [Article Influence: 18.3] [Reference Citation Analysis]
179 Goto S, Goto S. Is the answer to clinical questions provided by Bayesian network meta-analysis? Regarding the optimal duration of DAPT and the best subsequent SAPT. Eur Heart J Cardiovasc Pharmacother 2021;7:216-7. [PMID: 32424398 DOI: 10.1093/ehjcvp/pvaa032] [Reference Citation Analysis]
180 Kedhi E, Fabris E, van der Ent M, Buszman P, von Birgelen C, Roolvink V, Zurakowski A, Schotborgh CE, Hoorntje JCA, Eek CH, Cook S, Togni M, Meuwissen M, van Royen N, van Vliet R, Wedel H, Delewi R, Zijlstra F. Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ 2018;363:k3793. [PMID: 30279197 DOI: 10.1136/bmj.k3793] [Cited by in Crossref: 67] [Cited by in F6Publishing: 46] [Article Influence: 22.3] [Reference Citation Analysis]
181 Elmariah S, Mauri L, Doros G, Galper BZ, O'Neill KE, Steg PG, Kereiakes DJ, Yeh RW. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet 2015;385:792-8. [PMID: 25467565 DOI: 10.1016/S0140-6736(14)62052-3] [Cited by in Crossref: 122] [Cited by in F6Publishing: 30] [Article Influence: 17.4] [Reference Citation Analysis]
182 Rivas Rios JR, Franchi F, Rollini F, Angiolillo DJ. Diabetes and antiplatelet therapy: from bench to bedside. Cardiovasc Diagn Ther 2018;8:594-609. [PMID: 30498684 DOI: 10.21037/cdt.2018.05.09] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
183 Andó G, Costa F. Bleeding risk stratification in acute coronary syndromes. Is it still valid in the era of the radial approach? Postepy Kardiol Interwencyjnej 2015;11:170-3. [PMID: 26677354 DOI: 10.5114/pwki.2015.54007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
184 Mansour A, Bachelot-Loza C, Nesseler N, Gaussem P, Gouin-Thibault I. P2Y12 Inhibition beyond Thrombosis: Effects on Inflammation. Int J Mol Sci 2020;21:E1391. [PMID: 32092903 DOI: 10.3390/ijms21041391] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 20.0] [Reference Citation Analysis]
185 Palekar RU, Vemuri C, Marsh JN, Arif B, Wickline SA. Antithrombin nanoparticles inhibit stent thrombosis in ex vivo static and flow models. J Vasc Surg 2016;64:1459-67. [PMID: 26482989 DOI: 10.1016/j.jvs.2015.08.086] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
186 Nishikawa M, Takeda Y, Isomura N, Tanigawa T, Nanasato M, Tsukahara K, Kimura K, Takayama T, Hirayama A, Kato M, Nishikawa H, Nishimura Y, Isshiki T, Yokoi H; j-CHIPS group. Association between High Platelet Reactivity Following Dual Antiplatelet Therapy and Ischemic Events in Japanese Patients with Coronary Artery Disease Undergoing Stent Implantation. J Atheroscler Thromb 2020;27:13-24. [PMID: 31092743 DOI: 10.5551/jat.48934] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
187 Elliott J, Kelly SE, Bai Z, Liu W, Skidmore B, Boucher M, So DY, Wells GA. Optimal duration of dual antiplatelet therapy following percutaneous coronary intervention: protocol for an umbrella review. BMJ Open 2017;7:e015421. [PMID: 28377396 DOI: 10.1136/bmjopen-2016-015421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
188 Regueiro A, Cruz-Gonzalez I, Bethencourt A, Nombela-Franco L, Champagne J, Asmarats L, Jiménez-Quevedo P, Rodriguez-Gabella T, Rama-Merchan JC, Puri R, O'Hara G, Rodés-Cabau J. Long-term outcomes following percutaneous left atrial appendage closure in patients with atrial fibrillation and contraindications to anticoagulation. J Interv Card Electrophysiol 2018;52:53-9. [PMID: 29564664 DOI: 10.1007/s10840-018-0356-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
189 Kwon SW, Park SD, Moon J, Oh PC, Jang HJ, Park HW, Kim TH, Lee K, Suh J, Kang W. Complete Versus Culprit-Only Revascularization for ST-Segment Elevation Myocardial Infarction and Multivessel Disease in the 2nd Generation Drug-Eluting Stent Era: Data from the INTERSTELLAR Registry. Korean Circ J 2018;48:989-99. [PMID: 30334385 DOI: 10.4070/kcj.2017.0387] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
190 Stone GW, Hochman JS, Williams DO, Boden WE, Ferguson TB, Harrington RA, Maron DJ. Medical Therapy With Versus Without Revascularization in Stable Patients With Moderate and Severe Ischemia: The Case for Community Equipoise. J Am Coll Cardiol. 2016;67:81-99. [PMID: 26616030 DOI: 10.1016/j.jacc.2015.09.056] [Cited by in Crossref: 65] [Cited by in F6Publishing: 44] [Article Influence: 10.8] [Reference Citation Analysis]
191 Akinapelli A, Chen JP, Roy K, Donnelly J, Dawkins K, Huibregtse B, Hou D. Current State of Bioabsorbable Polymer-Coated Drug-Eluting Stents. Curr Cardiol Rev 2017;13:139-54. [PMID: 28017123 DOI: 10.2174/1573403X12666161222155230] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
192 Chaitman BR, Alexander KP, Cyr DD, Berger JS, Reynolds HR, Bangalore S, Boden WE, Lopes RD, Demkow M, Piero Perna G, Riezebos RK, McFalls EO, Banerjee S, Bagai A, Gosselin G, O'Brien SM, Rockhold FW, Waters DD, Thygesen KA, Stone GW, White HD, Maron DJ, Hochman JS; ISCHEMIA Research Group. Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons. Circulation 2021;143:790-804. [PMID: 33267610 DOI: 10.1161/CIRCULATIONAHA.120.047987] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 11.0] [Reference Citation Analysis]
193 Scott SA, Collet JP, Baber U, Yang Y, Peter I, Linderman M, Sload J, Qiao W, Kini AS, Sharma SK, Desnick RJ, Fuster V, Hajjar RJ, Montalescot G, Hulot JS. Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity. Clin Pharmacol Ther 2016;100:287-94. [PMID: 27213804 DOI: 10.1002/cpt.401] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
194 Chandiramani R, Cao D, Claessen BE, Sorrentino S, Guedeney P, Blum M, Goel R, Roumeliotis A, Krucoff M, Kozuma K, Ge J, Seth A, Makkar R, Bangalore S, Bhatt DL, Angiolillo DJ, Ruster K, Wang J, Saito S, Neumann FJ, Hermiller J, Valgimigli M, Mehran R. Sex-Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patient-Level Pooled Analysis From 4 Postapproval Studies. J Am Heart Assoc 2020;9:e014611. [PMID: 32223396 DOI: 10.1161/JAHA.119.014611] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
195 Ki YJ, Kang J, Park J, Han JK, Yang HM, Park KW, Kang HJ, Koo BK, Kim HS. Efficacy and Safety of Long-Term and Short-Term Dual Antiplatelet Therapy: A Meta-Analysis of Comparison between Asians and Non-Asians. J Clin Med 2020;9:E652. [PMID: 32121235 DOI: 10.3390/jcm9030652] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
196 Fierro JJ, Cave B, Khouzam RN. P2Y12 inhibitors: do they increase cancer risk? Ann Transl Med 2019;7:409. [PMID: 31660308 DOI: 10.21037/atm.2019.07.90] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
197 Reejhsinghani R, Lotfi AS. Prevention of stent thrombosis: challenges and solutions. Vasc Health Risk Manag 2015;11:93-106. [PMID: 25657588 DOI: 10.2147/VHRM.S43357] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
198 Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L; Dual Antiplatelet Therapy (DAPT) Study Investigators. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. JAMA 2015;313:1113-21. [PMID: 25781440 DOI: 10.1001/jama.2015.1671] [Cited by in Crossref: 64] [Cited by in F6Publishing: 49] [Article Influence: 10.7] [Reference Citation Analysis]
199 Tokuda T, Yamawaki M, Takahara M, Mori S, Makino K, Honda Y, Takafuji H, Takama T, Tsutsumi M, Sakamoto Y, Takimura H, Kobayashi N, Araki M, Hirano K, Ito Y. Comparison of Long-Term Clinical Outcomes of Lesions Exhibiting Focal and Segmental Peri-Stent Contrast Staining. J Am Heart Assoc 2016;5:e002878. [PMID: 26994133 DOI: 10.1161/JAHA.115.002878] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
200 Alfredsson J, Roe MT. Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications. J Am Heart Assoc 2015;4:e001897. [PMID: 25792126 DOI: 10.1161/JAHA.115.001897] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
201 Fanaroff AC, Kaltenbach LA, Peterson ED, Akhter MW, Effron MB, Henry TD, Wang TY. Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE-ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) Study. J Am Heart Assoc 2018;7:e007982. [PMID: 29437596 DOI: 10.1161/JAHA.117.007982] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
202 Ajjan RA, Kietsiriroje N, Badimon L, Vilahur G, Gorog DA, Angiolillo DJ, Russell DA, Rocca B, Storey RF. Antithrombotic therapy in diabetes: which, when, and for how long? Eur Heart J 2021;42:2235-59. [PMID: 33764414 DOI: 10.1093/eurheartj/ehab128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
203 Tefft BJ, Uthamaraj S, Harbuzariu A, Harburn JJ, Witt TA, Newman B, Psaltis PJ, Hlinomaz O, Holmes DR Jr, Gulati R, Simari RD, Dragomir-Daescu D, Sandhu GS. Nanoparticle-Mediated Cell Capture Enables Rapid Endothelialization of a Novel Bare Metal Stent. Tissue Eng Part A 2018;24:1157-66. [PMID: 29431053 DOI: 10.1089/ten.TEA.2017.0404] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
204 Woo HG, Lee HA, Ryu DR, Song TJ. Association of Mortality with Antiplatelet Treatment in Patients with Stent Placement or Angioplasty: A Population-Based Nested Case-Control Study. Yonsei Med J 2021;62:75-85. [PMID: 33381937 DOI: 10.3349/ymj.2021.62.1.75] [Reference Citation Analysis]
205 Fleming TR, DeMets DL, Roe MT, Wittes J, Calis KA, Vora AN, Meisel A, Bain RP, Konstam MA, Pencina MJ, Gordon DJ, Mahaffey KW, Hennekens CH, Neaton JD, Pearson GD, Andersson TL, Pfeffer MA, Ellenberg SS. Data monitoring committees: Promoting best practices to address emerging challenges. Clin Trials 2017;14:115-23. [PMID: 28359194 DOI: 10.1177/1740774516688915] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
206 Asher E, Abu-Much A, Goldenberg I, Segev A, Sabbag A, Mazin I, Shlezinger M, Atar S, Zahger D, Polak A, Beigel R, Matetzky S; Platelets and Thrombosis in Sheba-PLATIS Study Group. Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2). PLoS One 2016;11:e0157437. [PMID: 27310147 DOI: 10.1371/journal.pone.0157437] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
207 Costa F, Windecker S, Valgimigli M. Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies. Drugs 2017;77:1733-54. [PMID: 28853033 DOI: 10.1007/s40265-017-0806-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
208 Khan SU, Singh M, Valavoor S, Khan MU, Lone AN, Khan MZ, Khan MS, Mani P, Kapadia SR, Michos ED, Stone GW, Kalra A, Bhatt DL. Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis. Circulation 2020;142:1425-36. [PMID: 32795096 DOI: 10.1161/CIRCULATIONAHA.120.046308] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 27.0] [Reference Citation Analysis]
209 Howard CE, Nambi V, Jneid H, Khalid U. Extended Duration of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: How Long Is Too Long? J Am Heart Assoc 2019;8:e012639. [PMID: 31576769 DOI: 10.1161/JAHA.119.012639] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
210 Guedeney P, Mesnier J, Sorrentino S, Abcha F, Zeitouni M, Lattuca B, Silvain J, De Rosa S, Indolfi C, Collet JP, Kerneis M, Montalescot G. Early Aspirin Discontinuation Following Acute Coronary Syndrome or Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med 2020;9:E680. [PMID: 32138287 DOI: 10.3390/jcm9030680] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
211 Kelly CR, Kirtane AJ, Stant J, Stone GW, Minutello RM, Wong SC, Manuzon H, Gerow-Smith R, Kelley N, Rabbani LE. An Updated Protocol for Evaluating Chest Pain and Managing Acute Coronary Syndromes. Crit Pathw Cardiol 2017;16:7-14. [PMID: 28195937 DOI: 10.1097/HPC.0000000000000098] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
212 Collet JP, Silvain J, Kerneis M, Cuisset T, Meneveau N, Boueri Z, Barthélémy O, Rangé G, Cayla G, Belle EV, Elhadad S, Carrié D, Caussin C, Rousseau H, Aubry P, Monségu J, Sabouret P, O'Connor SA, Abtan J, Saint-Etienne C, Beygui F, Vicaut E, Montalescot G; ARCTIC Investigators. Clinical Outcome of First- vs Second-Generation DES According to DAPT Duration: Results of ARCTIC-Generation. Clin Cardiol 2016;39:192-200. [PMID: 26880570 DOI: 10.1002/clc.22512] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
213 Bittl JA, He Y. Bayesian Analysis: A Practical Approach to Interpret Clinical Trials and Create Clinical Practice Guidelines. Circ Cardiovasc Qual Outcomes 2017;10:e003563. [PMID: 28798016 DOI: 10.1161/CIRCOUTCOMES.117.003563] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
214 Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J 2019;40:2632-53. [PMID: 31116395 DOI: 10.1093/eurheartj/ehz372] [Cited by in Crossref: 128] [Cited by in F6Publishing: 75] [Article Influence: 128.0] [Reference Citation Analysis]
215 Fanaroff AC, Hasselblad V, Roe MT, Bhatt DL, James SK, Steg PG, Gibson CM, Ohman EM. Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. Int J Cardiol 2017;241:87-96. [PMID: 28320608 DOI: 10.1016/j.ijcard.2017.03.046] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
216 Roe MT, Cyr DD, Eckart D, Schulte PJ, Morse MA, Blackwell KL, Ready NE, Zafar SY, Beaven AW, Strickler JH, Onken JE, Winters KJ, Houterloot L, Zamoryakhin D, Wiviott SD, White HD, Prabhakaran D, Fox KA, Armstrong PW, Ohman EM; TRILOGY ACS Investigators. Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. Eur Heart J 2016;37:412-22. [PMID: 26637834 DOI: 10.1093/eurheartj/ehv611] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
217 Ribera A, Ferreira-Gonzalez I, Marsal JR, Oristrell G, Faixedas MT, Rosas A, Tizón-Marcos H, Rojas S, Labata C, Cardenas M, Homs S, Tomas-Querol C, Garcia-Picart J, Gomez-Hospital JA, Pijoan JI, Masotti M, Mauri J, Garcia Dorado D; VESA Study and Codi IAM Investigators. Persistence with dual antiplatelet therapy after percutaneous coronary intervention for ST-segment elevation acute coronary syndrome: a population-based cohort study in Catalonia (Spain). BMJ Open 2019;9:e028114. [PMID: 31340964 DOI: 10.1136/bmjopen-2018-028114] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
218 Bueno H, Pocock S, Danchin N, Annemans L, Gregson J, Medina J, Van de Werf F. International patterns of dual antiplatelet therapy duration after acute coronary syndromes. Heart 2017;103:132-8. [PMID: 27504002 DOI: 10.1136/heartjnl-2016-309509] [Cited by in Crossref: 34] [Cited by in F6Publishing: 16] [Article Influence: 6.8] [Reference Citation Analysis]
219 Zhou Y, Yasumoto A, Lei C, Huang CJ, Kobayashi H, Wu Y, Yan S, Sun CW, Yatomi Y, Goda K. Intelligent classification of platelet aggregates by agonist type. Elife 2020;9:e52938. [PMID: 32393438 DOI: 10.7554/eLife.52938] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 15.0] [Reference Citation Analysis]
220 Ariotti S, Gargiulo G, Windecker S, Valgimigli M. Time for science to catch up with clinical practice? J Thorac Dis 2015;7:E603-6. [PMID: 26793370 DOI: 10.3978/j.issn.2072-1439.2015.12.26] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
221 Morino Y, Terashita D, Otake H, Kikuchi T, Fusazaki T, Kuriyama N, Suzuki T, Ito Y, Hibi K, Tanaka H, Ishihara S, Kataoka T, Morita T, Otsuka Y, Hayashi T, Tanabe K, Shinke T. Early vascular responses to everolimus-eluting cobalt-chromium stent in the culprit lesions of st-elevation myocardial infarction: results from a multicenter prospective optical coherence tomography study (MECHANISM-AMI 2-week follow-up study). Cardiovasc Interv Ther 2019;34:14-24. [PMID: 29318464 DOI: 10.1007/s12928-017-0507-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
222 Gurbel PA, Myat A, Kubica J, Tantry US. State of the art: Oral antiplatelet therapy. JRSM Cardiovasc Dis 2016;5:2048004016652514. [PMID: 27298725 DOI: 10.1177/2048004016652514] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
223 Elmariah S. Formal comment to Toyota et al.: Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: A comparison between the DAPT study and 9 other trials evaluating DAPT duration. PLoS One 2017;12:e0184513. [PMID: 28931024 DOI: 10.1371/journal.pone.0184513] [Reference Citation Analysis]
224 Everaert B, Wykrzykowska JJ, Koolen J, van der Harst P, den Heijer P, Henriques JP, van der Schaaf R, de Smet B, Hofma SH, Diletti R, Weevers A, Hoorntje J, Smits P, van Geuns RJ. Recommendations for the use of bioresorbable vascular scaffolds in percutaneous coronary interventions : 2017 revision. Neth Heart J 2017;25:419-28. [PMID: 28643297 DOI: 10.1007/s12471-017-1014-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
225 Fanaroff AC, Cyr D, Neely ML, Bakal J, White HD, Fox KAA, Armstrong PW, Lopes RD, Ohman EM, Roe MT. Days Alive and Out of Hospital: Exploring a Patient-Centered, Pragmatic Outcome in a Clinical Trial of Patients With Acute Coronary Syndromes. Circ Cardiovasc Qual Outcomes 2018;11:e004755. [PMID: 30562068 DOI: 10.1161/CIRCOUTCOMES.118.004755] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
226 Liu M, Zhuang X, Chen X, Zhang S, Yang D, Zhong X, Xiong Z, Lin Y, Zhou H, Fan Y, Xie P, Huang Y, Wang L, Liao X. Antiplatelet strategy in primary and secondary prevention of cardiovascular disease in patients with type 2 diabetes mellitus: A perspective from the guideline appraisal. J Diabetes Investig 2021;12:99-108. [PMID: 32543044 DOI: 10.1111/jdi.13324] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
227 Kikkert WJ, Damman P. Optimal duration of dual antiplatelet therapy for coronary artery disease. Neth Heart J 2018;26:321-33. [PMID: 29713989 DOI: 10.1007/s12471-018-1113-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
228 Sharma R, Kumar P, Prashanth SP, Belagali Y. Dual Antiplatelet Therapy in Coronary Artery Disease. Cardiol Ther 2020;9:349-61. [PMID: 32804330 DOI: 10.1007/s40119-020-00197-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
229 Baaten CC, Veenstra LF, Wetzels R, van Geffen JP, Swieringa F, de Witt SM, Henskens YM, Crijns H, Nylander S, van Giezen JJ, Heemskerk JW, van der Meijden PE. Gradual increase in thrombogenicity of juvenile platelets formed upon offset of prasugrel medication. Haematologica 2015;100:1131-8. [PMID: 26113418 DOI: 10.3324/haematol.2014.122457] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
230 Xu Y, Shen Y, Chen D, Zhao P, Jiang J. Efficacy and Safety of Dual Antiplatelet Therapy in Patients Undergoing Coronary Stent Implantation: A Systematic Review and Network Meta-Analysis. J Interv Cardiol 2021;2021:9934535. [PMID: 34035674 DOI: 10.1155/2021/9934535] [Reference Citation Analysis]
231 Liu Y, Zhou X, Jiang H, Gao M, Wang L, Shi Y, Gao J. Percutaneous coronary intervention strategies and prognosis for graft lesions following coronary artery bypass grafting. Exp Ther Med 2015;9:1656-64. [PMID: 26136874 DOI: 10.3892/etm.2015.2366] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
232 Woods LT, Forti KM, Shanbhag VC, Camden JM, Weisman GA. P2Y receptors for extracellular nucleotides: Contributions to cancer progression and therapeutic implications. Biochem Pharmacol 2021;187:114406. [PMID: 33412103 DOI: 10.1016/j.bcp.2021.114406] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
233 Guedeney P, Collet JP. Diagnosis and Management of Acute Coronary Syndrome: What is New and Why? Insight From the 2020 European Society of Cardiology Guidelines. J Clin Med 2020;9:E3474. [PMID: 33126578 DOI: 10.3390/jcm9113474] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
234 Ueshima D, Yoshikawa S, Sasaoka T, Hatano Y, Kurihara K, Maejima Y, Isobe M, Ashikaga T. The Hypercholesterolemia Paradox in Percutaneous Coronary Intervention: An Analysis of a Multicenter PCI Registry. Intern Med 2019;58:345-53. [PMID: 30210130 DOI: 10.2169/internalmedicine.1553-18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
235 Soden PA, Zettervall SL, Ultee KH, Landon BE, O'Malley AJ, Goodney PP, DeMartino RR, Arya S, Schermerhorn ML; Society for Vascular Surgery Vascular Quality Initiative. Dual antiplatelet therapy is associated with prolonged survival after lower extremity revascularization. J Vasc Surg 2016;64:1633-1644.e1. [PMID: 27575814 DOI: 10.1016/j.jvs.2016.05.098] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 4.4] [Reference Citation Analysis]
236 Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. The Platelet Lifeline to Cancer: Challenges and Opportunities. Cancer Cell. 2018;33:965-983. [PMID: 29657130 DOI: 10.1016/j.ccell.2018.03.002] [Cited by in Crossref: 131] [Cited by in F6Publishing: 120] [Article Influence: 43.7] [Reference Citation Analysis]